In agreement with the previous finding that treatment of SPOP‐mutated PCa cells with either the BET inhibitor JQ1 or the CBP/p300 inhibitor C646 invariably diminishes BRD4 enrichment at its binding loci (Zhang et al, 2017), we demonstrated in the current study that SPOP mutant PCa cell lines, organoids, and PDX tumors were sensitive to co‐treatment with JQ1 and the CBP/p300 inhibitor CPI‐637. Here, BRD4 is linked to posterior cortical atrophy.